基于ABVS影像组学与临床因素的列线图预测HR+/HER2-乳腺癌1-2枚前哨淋巴结阳性患者≤3枚腋窝淋巴结阳性
本研究纳入511例早期乳腺癌患者(A医院362例训练、B医院149例验证),构建整合ABVS影像组学与临床特征的列线图,预测HR+/HER2-且1-2枚前哨淋巴结阳性患者≤3枚腋窝淋巴结阳性。训练组AUC 0.910、验证组0.882,优于无影像组学的临床列线图(AUC 0.796和0.782),校准曲线与HL检验(P值0.688和0.691)确认稳健性,DCA显示在特定阈值概率下净获益更优。
要点
- 列线图整合ABVS影像组学与临床因素,训练组AUC 0.910、验证组0.882。
- 阳性前哨淋巴结数(OR=0.077)、无阴性前哨淋巴结(OR=11.138)、脉管侵犯(OR=0.248)及rad-score(OR=0.003)与≤3枚阳性腋窝淋巴结相关。
- 无影像组学的临床列线图训练组AUC 0.796、验证组0.782,联合模型判别能力更优。
核心结论
- 整合ABVS影像组学与临床数据的临床-影像组学列线图可预测HR+/HER2-且1-2枚前哨淋巴结阳性患者≤3枚阳性腋窝淋巴结,帮助肿瘤科医生识别基因组检测候选者、避免腋窝淋巴结清扫。
研究设计与样本
- 研究纳入511例早期乳腺癌患者,A医院362例为训练组、B医院149例为验证组。
- 采用LASSO逻辑回归筛选主要特征,构建临床-影像组学列线图预测HR+/HER2-且1-2枚前哨淋巴结阳性患者≤3枚阳性腋窝淋巴结的概率。
- 以ROC曲线评估判别能力,校准曲线确认校准度,Hosmer-Lemeshow检验评估拟合度,决策曲线分析评估临床净获益。
诊断标准与关键数值
- 训练组81.2%、验证组83.2%的患者≤3枚转移性腋窝淋巴结。
- 阳性前哨淋巴结数OR=0.077、无阴性前哨淋巴结OR=11.138、脉管侵犯OR=0.248、rad-score OR=0.003,均与≤3枚阳性腋窝淋巴结显著相关。
- 临床-影像组学列线图训练组AUC 0.910、验证组0.882;无影像组学的临床列线图训练组AUC 0.796、验证组0.782。
- 校准曲线与HL检验P值分别为0.688和0.691。
临床应用与阅片要点
- 作者认为该列线图有助于肿瘤科医生识别适合基因组检测的候选者,从而避免腋窝淋巴结清扫。
- 作者指出在精准医学时代,基因组检测联合前哨淋巴结活检可优化手术与全身治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: In HR+ /HER2- breast cancer patients with ≤ 3 positive axillary lymph nodes (ALNs), genomic tests can streamline chemotherapy decisions. Current studies, centered on tumor metrics, miss broader patient insights. Automated Breast Volume Scanning (ABVS) provides advanced 3D imaging, and its potential synergy with radiomics for ALN evaluation is untapped.
OBJECTIVE: This study sought to combine ABVS radiomics and clinical characteristics in a nomogram to predict ≤ 3 positive ALNs in HR+ /HER2- breast cancer patients with 1-2 positive sentinel lymph nodes (SLNs), guiding clinicians in genetic test candidate selection.
METHODS: We enrolled 511 early-stage breast cancer patients: 362 from A Hospital for training and 149 from B Hospital for validation. Using LASSO logistic regression, primary features were identified. A clinical-radiomics nomogram was developed to predict the likelihood of ≤ 3 positive ALNs in HR+ /HER2- patients with 1-2 positive SLNs. We assessed the discriminative capability of the nomogram using the ROC curve. The model's calibration was confirmed through a calibration curve, while its fit was evaluated using the Hosmer-Lemeshow (HL) test. To determine the clinical net benefits, we employed the Decision Curve Analysis (DCA).
RESULTS: In the training group, 81.2% patients had ≤ 3 metastatic ALNs, and 83.2% in the validation group. We developed a clinical-radiomics nomogram by analyzing clinical characteristics and rad-scores. Factors like positive SLNs (OR=0.077), absence of negative SLNs (OR=11.138), lymphovascular invasion (OR=0.248), and rad-score (OR=0.003) significantly correlated with ≤ 3 positive ALNs. The clinical-radiomics nomogram, with an AUC of 0.910 in training and 0.882 in validation, outperformed the rad-score-free clinical nomogram (AUCs of 0.796 and 0.782). Calibration curves and the HL test (P values 0.688 and 0.691) confirmed its robustness. DCA showed the clinical-radiomics nomogram provided superior net benefits in predicting ALN burden across specific threshold probabilities.
CONCLUSION: We developed a clinical-radiomics nomogram that integrated radiomics from ABVS images and clinical data to predict the presence of ≤ 3 positive ALNs in HR+ /HER2- patients with 1-2 positive SLNs, aiding oncologists in identifying candidates for genomic tests, bypassing ALND. In the era of precision medicine, combining genomic tests with SLN biopsy refines both surgical and systemic patient treatments.
引用
- Hu B, Xu Y, Gong H, et al. Nomogram Utilizing ABVS Radiomics and Clinical Factors for Predicting ≤ 3 Positive Axillary Lymph Nodes in HR+ /HER2- Breast Cancer with 1-2 Positive Sentinel Nodes. Acad Radiol. 2024. PMID: 38383259. doi:10.1016/j.acra.2024.01.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。